In:
International Journal of Cancer, Wiley, Vol. 148, No. 10 ( 2021-05-15), p. 2614-2627
Abstract:
What's new? In breast cancer, a pathologic complete response (pCR) after neoadjuvant therapy (NAT) can predict long‐term outcome. However, rates of pCR differ according to EBC subtype. So what is the most useful approach to determine early response? In this prospective study, the authors compared MRI, ultrasound, and Ki‐67 status after three weeks of NAT. They found that MRI and Ki‐67 had higher sensitivity than ultrasound in HR‐/HER2+ and HR‐/HER2‐ tumors, while all three methods were similar for HR+/HER2+ tumors. These findings could guide identification of candidates for therapy de‐escalation or escalation.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink